Private Equity

Updated:

Biomark Capital

Biomark Capital is a Greenwich-based asset manager focused on early-stage venture investments.

Biomark Capital logo

Biomark Capital

Biomark Capital invests in early, mid, and late-stage life science companies. The firm focuses on companies with novel approaches to diagnostics, therapeutics, medical devices, and digital health. Biomark has made 30 investments, including a Series A investment in Naluri on June 09, 2021, and has facilitated 7 portfolio exits, including Strand Life Sciences on September 03, 2021.

General information

Firm type

Private Equity

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Greenwich

Corporate office

Greenwich, United States

Sector focus

Venture Capital

Frequently asked questions

What stages does Biomark Capital target?

The firm lists coverage of early-stage seed, start-up, expansion, and general venture.

Where is Biomark Capital based?

Headquarters are in Greenwich, United States.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Greenwich Private Equity profiles